Dipyridamole/Prednisolone

双嘧达莫/泼尼松龙

Report date: 2022/11/25 17:30:05

Base Information

Drug NameDipyridamole/Prednisolone
Drug Alias Name泼尼松龙/双嘧达莫Prednisolone and Dipyridamole泼尼松龙+双嘧达莫Dipyridamole and Prednisolone双嘧达莫泼尼松龙 +[8] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonists3',5'-cyclic phosphodiesterase inhibitors
TargetsGlucocorticoid receptor3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsOsteoarthritis, KneeArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[12] 
CombinationsYes PrednisoloneDipyridamole
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZalicus Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZalicus Inc
Active IndicationsN/A
Inactive IndicationsOsteoarthritis, KneeArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A